HUMIRA is a TNF blocker medicine that affects the immune system and can lower the body's ability to fight infections. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. People should be tested for TB before HUMIRA use and monitored for signs and symptoms of TB during therapy, even if their TB test was negative. People at risk of TB may be treated with medicine for TB. Treatment with HUMIRA should not be started in a person with an active infection, unless approved by a doctor. HUMIRA should be stopped if a person develops a serious infection. People should tell their doctor if they live in or have been to a region where certain fungal infections are common, as these infections may happen or become more severe if people use HUMIRA. People should tell their doctor if they have had TB or hepatitis B, are prone to infections, or have symptoms such as fever, fatigue, cough, or sores.
Palforzia is seen as an important test case for a new generation of therapies expected to transform how food allergies are treated. Doctors who have had few tools other than counseling their patients to assiduously avoid peanuts expect that other drugs will follow — additional drugs for the peanut allergy, as well as egg and tree nut allergies. Aimmune Therapeutics, which makes Palforzia, has several other food allergy treatments in its pipeline.
Lannett Company (NYSE:LCI), a small-cap drug manufacturer, received FDA approval for Numbrino, the first branded drug in the company's 78-year history. The nasal spray will be marketed to doctors as a local anesthetic for minor surgeries around the nasal cavities of patients, but will not be available in retail pharmacies.
Sophia Genetics has named Philippe Menu as chief medical officer. Menu joined the Swiss bioinformatics company from McKinsey, where he was co-leader of the McKinsey Cancer Center. A physician with a PhD in molecular biology, Menu primarily advised pharmaceutical and biotech companies in the development of new therapies and diagnostics in oncology and rare diseases. At Sophia, he will lead the firm's medical strategy.
Even though DNA sequencing technology is becoming increasingly accessible, it is still difficult to glean helpful information from an individual’s DNA. That is because there is a lack of reference data compiled from other people’s DNA. Most reference data is currently curated by academic institutions and is often compiled in different formats, making it difficult for doctors and researchers to use.
“Instead of using a specific test for tuberculosis, the doctor would take a sample, sequence that sample and transform that biology into data, and then exhaustively search that data against all the pathogens and they’ll be able to tell you if you have TB, the type of TB and maybe this TB has antibiotic resistance,” he said.
Through its Genomic Medicine Initiative (GMI), UCSF has integrated data from a comprehensive cancer genetic testing program into the electronic medical records of patients at the UCSF Medical Center. Not only does it allow for continuity of care with all testing and treatment results tied to the same electronic record, but it also allows physicians and researchers to identify larger patterns in the data that can lead to the development of better treatments – which is known as precision medicine.
Bempedoic acid is a once-a-day oral medication that will be commercially known as Nexletol. The FDA approved it for use with a healthy diet and the maximum dose of statins a patient tolerates. Studies show the new drug can reduce what doctors call low-density lipoprotein cholesterol, what you may know as LDL, the "bad" cholesterol that can lead to heart problems or strokes.
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.